Innovative Adaptation & Dissemination of CER Products: Autism(iADAPT-ASD)

创新适应

• 批准号: 8009394
• 负责人: Mark Jonathan Harris
• 金额: $ 148.62万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2013-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8009394
• 关键词: Innovative; Adaptation; Dissemination; CER; Products

DESCRIPTION (provided by applicant): Autism and autism spectrum disorders (ASD) are pervasive neurodevelopmental disorders first described over sixty years ago and diagnosed on the basis of significant impairments in social, communicative, cognitive and behavioral functioning. Symptoms persist throughout life, disrupt families and lead to significant disability; thus, ASD presents major public health challenges. There is no cure and no global consensus regarding which intervention strategy is most effective, with chronic management often being required. Given the complexity of ASD and associated therapies, it is clear that teachers, clinicians and families need guidance in selecting appropriate treatments. We propose to increase the impact, use and application of two AHRQ comparative effectiveness (CER) products that reference ASD therapeutics, adapting both their content and delivery mechanism to improve their penetration, impact and use at the health and educational systems, clinical practice, caregiver and family levels. Our multidisciplinary team brings together faculty from the School of Cinematic Arts, Annenberg School for Communication & Journalism and Rossier School of Education at the University of Southern California with a nationwide network of experts on ASD therapeutics. Our collective expertise is in academy award-winning documentary film production; health communication; quantitative evaluation; and behavioral and pharmacologic ASD treatments. We will develop, implement, and evaluate highly interactive and engaging evidence-based interventions as customizations of CER products that target important audiences, public systems and settings that are not already specifically targeted or reached by the original CER review products. We specifically will target important clinician, parent and teacher audiences of over 16,000 stakeholders that include: (1) a nationwide sample of 10,000 parents of ASD children in the Interactive Autism Network (IAN); (2) a difficult-to-reach population of 350 parents of ASD children, primarily from traditionally underserved minority groups in the city of Philadelphia; (3) 4,000 teachers (over half from minority populations) in three large Southern California public school districts who have contact with ASD children; and (4) 2,000 Medicaid-licensed clinicians across Pennsylvania who treat ASD under the auspices of the Department of Public Welfare. We will employ novel methods of adaption and innovative mechanisms through technology-based and social networking dissemination channels to create highly interactive and emotionally engaging documentary vignettes that can be rapidly and easily downloaded from an internet website. Our dissemination approach will incorporate pre- and post- intervention exposure to quantitatively evaluate the efficacy and impact of our intervention in the targeted audiences. Our novel approaches to both content and delivery will enhance the translation of new scientific ASD evidence in an accelerated format and the integration of this evidence into practice and decision-making in families, the education system, the health care system and public policy. All work products will be broadly shared with the scientific community. PUBLIC HEALTH RELEVANCE: We will develop, implement, and evaluate highly interactive and engaging evidence-based interventions for disseminating information about treatments for autism and autism spectrum disorders to over 16,000 individuals in important clinician, parent and teacher audiences. We partner with a social networking site for parents, public school districts and a state healthcare delivery system. Our novel approaches to both content and delivery will enhance the translation of new scientific evidence on ASD therapeutics in an accelerated format and its integration into practice and decision-making in families, the education system, the health care system and public policy.

描述（由申请人提供）：自闭症和自闭症谱系障碍（ASD）是一种普遍性神经发育障碍，六十多年前首次被描述，并根据社交、沟通、认知和行为功能的严重损害进行诊断。症状持续一生，破坏家庭并导致严重残疾;因此，ASD提出了重大的公共卫生挑战。对于哪种干预策略最有效，没有治愈方法，也没有全球共识，往往需要长期管理。鉴于ASD和相关疗法的复杂性，很明显，教师，临床医生和家庭需要指导选择适当的治疗方法。我们建议增加两个AHRQ比较有效性（CER）产品的影响，使用和应用，参考ASD治疗，调整其内容和交付机制，以提高其在健康和教育系统，临床实践，护理人员和家庭层面的渗透，影响和使用。我们的多学科团队汇集了来自南加州大学电影艺术学院，安嫩伯格传播与新闻学院和Rossier教育学院的教师，以及ASD治疗专家的全国网络。我们的集体专业知识是在学院获奖纪录片制作;健康传播;定量评估;和行为和药理学ASD治疗。我们将开发，实施和评估高度互动和参与的循证干预措施，作为CER产品的定制，针对原始CER审评产品尚未明确针对或触及的重要受众，公共系统和环境。我们将特别针对超过16，000名利益相关者的重要临床医生，家长和教师受众，其中包括：（1）互动自闭症网络（IAN）中的10，000名ASD儿童家长的全国样本;（2）难以接触的350名ASD儿童家长，主要来自费城传统上服务不足的少数群体;（3）南加州三个大型公立学区的4,000名教师（一半以上来自少数民族），他们与自闭症儿童有接触;（4）宾夕法尼亚州有2,000名医疗补助许可的临床医生，他们在公共福利部的赞助下治疗自闭症。我们将采用新的改编方法和创新机制，通过基于技术和社交网络的传播渠道，创造高度互动和情感吸引力的纪录片小插曲，可以快速和容易地从互联网网站下载。我们的传播方法将包括干预前后的接触，以定量评估我们的干预在目标受众中的功效和影响。我们对内容和交付的新方法将以加速的形式加强新的科学ASD证据的翻译，并将这些证据整合到家庭，教育系统，医疗保健系统和公共政策的实践和决策中。所有工作成果将与科学界广泛分享。 公共卫生相关性：我们将开发，实施和评估高度互动和参与的循证干预措施，以向重要的临床医生，家长和教师受众中的16，000多人传播自闭症和自闭症谱系障碍治疗信息。我们与家长，公立学区和国家医疗保健提供系统的社交网站合作。我们对内容和交付的新方法将以加速的形式促进ASD治疗的新科学证据的翻译，并将其融入家庭，教育系统，医疗保健系统和公共政策的实践和决策中。